Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058965 · ClinicalTrials.gov registry record · Early Phase 1
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
A Early Phase 1 study, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT03058965: Completed Early Phase 1 study, sponsored by Molecular NeuroImaging.
NCT03058965 is a Early Phase 1 study that has completed, run by Molecular NeuroImaging. The registered enrollment target is 12 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03058965, a Early Phase 1 study, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The overall goal of this imaging trial is to evaluate \[18F\]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).
Primary Outcome
Descriptive statistics will be applied to describe the tau deposition by region as measured by \[18F\]MNI-958.
Interventions
- DRUG [18F]Florbetapir
- DRUG DaTscan
- DRUG [18F]MNI-958
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2018-05-11 |
| Phase | Early Phase 1 |
What the finished NCT03058965 record still lists
NCT03058965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 3 interventions - of which [18F]Florbetapir is the first listed.
NCT03058965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03058965 about?
NCT03058965 is a clinical study titled "Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain". The overall goal of this imaging trial is to evaluate \[18F\]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).
What is the current status of trial NCT03058965?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2016-11-29. Estimated completion is 2018-05-11.
What interventions are being tested in trial NCT03058965?
The interventions under investigation include: [18F]Florbetapir (DRUG), DaTscan (DRUG), [18F]MNI-958 (DRUG).
Who is sponsoring clinical trial NCT03058965?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03058965's enrollment target sits among peer trials
12 1529th of 2000 higher than 401 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI